Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers

European Journal of Pharmaceutical Sciences

Volumn 43, Issue 3, 2011, Pages 141-150

  Lappin, Graham ^a   Shishikura, Yoko ^a   Jochemsen, Roeline ^b   Weaver, Richard John ^b   Gesson, Charlotte ^b   Brian Houston, J ^c   Oosterhuis, Berend ^d   Bjerrum, Ole J ^e   Grynkiewicz, Grzegorz ^f   Alder, Jane ^c   Rowland, Malcolm ^c   Garner, Colin ^a,g  

^a Xceleron Ltd   (United Kingdom)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d PRA Health Sciences   (Netherlands)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

^g Garner Consulting   (United Kingdom)

Author keywords

Absolute oral bioavailability; Accelerator mass spectrometry; Clarithromycin; Microdosing; Pharmacokinetic linearity; Sumatriptan

Indexed keywords

CARBON 14; CLARITHROMYCIN; PARACETAMOL; PHENOBARBITAL; PROPAFENONE; SUMATRIPTAN SUCCINATE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG MICRODOSE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLARITHROMYCIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHENOBARBITAL; PROPAFENONE; SUMATRIPTAN;

EID: 79956356127     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.04.009     Document Type: Article

References (70)

1. Abernethy, D.R., Divoll, M., Greenblatt, D.J., Ameer, B., 1982. Obesity, sex, and acetaminophen disposition. Clin. Pharmacol. Ther. 31 (6), 783-790.
2. Albert, K.S., Sedman, A.J., Wilkinson, P., Stoll, R.G., Murray, W.J., Wagner, J.G., 1974. Bioavailability studies of acetaminophen and nitrofurantoin. J. Clin. Pharmacol. 14 (5-6), 264-270.
3. Arboix, M., Puigdemont, A., Moya, A., Cinca, J., 1985. Pharmacokinetics of intravenous propafenone in patients with episodes of paroxysmal supraventricular tachycardia. Methods Find Exp Clin Pharmacol 7 (8), 435-438. (Pubitemid 16253188)
4. Beaumont, K., Smith, D.A., 2009. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr. Opin. Drug. Discov. Devel. 12 (1), 61-71.
5. Bertino Jr., J.S., Greenberg, H.E., Reed, M.D., 2007. American college of clinical pharmacology position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 47 (4), 418-422.
6. Brunton, L.L., Lazo, J.S., Parker, K.L., 2006. Goodman and Gilman's, The Pharmacological Basis of Therapeutics. McGraw-Hill, New York.
7. Burgess, E., Duff, H., Wilkes, P., 1989. Propafenone disposition in renal insufficiency and renal failure. J. Clin. Pharmacol. 29 (2), 112-113.
8. Chu, S., Park, Y., Locke, C., Wilson, D.S., Cavanaugh, J.C., 1992a. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 32 (1), 32-36.
9. Chu, S.Y., Deaton, R., Cavanaugh, J., 1992b. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother. 36 (5), 1147-1150.
10. Chu, S.Y., Sennello, L.T., Bunnell, S.T., Varga, L.L., Wilson, D.S., Sonders, R.C., 1992c. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob. Agents Chemother. 36 (11), 2447-2453.
11. Chu, S.Y., Wilson, D.S., Guay, D.R., Craft, C., 1992d. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J. Clin. Pharmacol. 32 (11), 1045-1049.
12. Clements, J.A., Heading, R.C., Nimmo, W.S., Prescott, L.F., 1978. Kinetics of acetaminophen absorption and gastric emptying in man. Clin. Pharmacol. Ther. 24 (4), 420-431.
13. Crighton, I.M., Martin, P.H., Hobbs, G.J., Cobby, T.F., Fletcher, A.J., Stewart, P.D., 1998. A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. Anesth. Analg. 87 (2), 445-449.
14. Cubitt, H.E., Houston, B., Galetin, A., 2011. Prediction of drug clearance by sulfation - utility of human hepatic and intestinal cytosolic data. Drug Metab. Dispos. 39 (5), 864-873.
15. Davey, P.G., 1991. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J. Hosp. Infect. 19 (Suppl. A), 29-37.
16. Dechant, K.L., Clissold, S.P., 1992. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 43 (5), 776-798.
17. Divoll, M., Abernethy, D.R., Ameer, B., Greenblatt, D.J., 1982a. Acetaminophen kinetics in the elderly. Clin. Pharmacol. Ther. 31 (2), 151-156.
18. Divoll, M., Ameer, B., Abernethy, D.R., Greenblatt, D.J., 1982b. Age does not alter acetaminophen absorption. J. Am. Geriatr. Soc. 30 (4), 240-244.
19. Dixon, C.M., Park, G.R., Tarbit, M.H., 1994. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem. Pharmacol. 47 (7), 1253-1257.
20. Douglas, A.P., Savage, R.L., Rawlins, M.D., 1978. Paracetamol (acetaminophen) kinetics in patients with Gilber's syndrome. Eur. J. Clin. Pharmacol. 13 (3), 209-212.
21. Duquesnoy, C., Mamet, J.P., Sumner, D., Fuseau, E., 1998. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur. J. Pharm. Sci. 6 (2), 99-104.
22. Erah, P.O., Goddard, A.F., Barrett, D.A., Shaw, P.N., Spiller, R.C., 1997. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 39 (1), 5-12.
23. Ferrari, A., Pinetti, D., Bertolini, A., Coccia, C., Sternieri, E., 2008. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur. J. Clin. Pharmacol. 64 (5), 489-495.
24. Ferrero, J.L., Bopp, B.A., Marsh, K.C., Quigley, S.C., Johnson, M.J., Anderson, D.J., Lamm, J.E., Tolman, K.G., Sanders, S.W., Cavanaugh, J.H., et al., 1990. Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. 18 (4), 441-446.
25. Forrest, J.A., Clements, J.A., Prescott, L.F., 1982. Clinical pharmacokinetics of paracetamol. Clin. Pharmacokinet. 7 (2), 93-107.
26. Fowler, P.A., Lacey, L.F., Thomas, M., Keene, O.N., Tanner, R.J., Baber, N.S., 1991. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. 31 (5), 291-294.
27. Fraschini, F., Scaglione, F., Demartini, G., 1993. Clarithromycin clinical pharmacokinetics. Clin. Pharmacokinet. 25 (3), 189-204.
28. Garner, C., 2010. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2 (3), 429-440.
29. Giani, P., Landolina, M., Giudici, V., Bianchini, C., Ferrario, G., Marchi, S., Riva, E., Latini, R., 1988. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. Eur. J. Clin. Pharmacol. 34 (2), 187-194.
30. Haefeli, E.W., Vozeh, S., Ha, H.R., Follath, F., 1990. Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin. Pharmacol. Ther. 48 (3), 245-254.
31. Halifax, D., Foster, J.A., Houston, B., Mackenzie, P.I., 2010. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm. Res. 27, 2150-2161.
32. Hii, J.T., Duff, H.J., Burgess, E.D., 1991. Clinical pharmacokinetics of propafenone. Clin. Pharmacokinet. 21 (1), 1-10.
33. Hollmann, M., Brode, E., Hotz, D., Kaumeier, S., Kehrhahn, O.H., 1983. Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung 33 (5), 763-770. (Pubitemid 13087997)
34. ICH-M3, 2009. ICH Topic M3 Note for Guidance on non-clinical safety pharmacology studies for human pharmaceuticals CPMP/ICH/286/95 (December 2009).
35. Ings, R., 2009. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 1 (17), 1293-1305.
36. Komura, H., Iwaki, M., 2005. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity. Drug Metab. Dispos. 33 (6), 726-732.
37. Lacey, L.F., Hussey, E.K., Fowler, P.A., 1995. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur. J. Clin. Pharmacol. 47 (6), 543-548.
38. Lappin, G., 2010. Microdosing: current and the future. Bioanalysis 2 (3), 509-517.
39. Lappin, G., Garner, C., 2008. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4 (12), 1499-1506.
40. Lappin, G., Kuhnz, W., Jochemsen, R., Kneer, J., Chaudhary, A., Oosterhuis, B., Drijfhout, W.J., Rowland, M., Garner, R.C., 2006a. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther. 80 (3), 203-215.
41. Lappin, G., Rowland, M., Garner, R.C., 2006b. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol. 2 (3), 419-427.
42. Lappin, G., Shishikura, Y., Jochemsen, R., Weaver, R.J., Gesson, C., Houston, B., Oosterhuis, B., Bjerrum, O.J., Rowland, M., Garner, C., 2010. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur. J. Pharm. Sci. 40, 125-131.
43. Lappin, G., Simpson, M., Shishikura, Y., Garner, C., 2008. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal. Biochem. 378, 93-95.
44. Lewis, D.F., 2009. Early human studies of investigational agents: dose or microdose. Br. J. Clin. Pharmacol. 67 (3), 277-279.
45. Mager, D.E., 2006. Target-mediated drug disposition and dynamics. Biochem. Pharmacol. 72 (1), 1-10.
46. Miners, J.O., Knights, K.M., Houston, J.B., Mackenzie, P.I., 2006. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol. 71 (11), 1531-1539.
47. Moore, K.H., Leese, P.T., McNeal, S., Gray, P., O'Quinn, S., Bye, C., Sale, M., 2002. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin. Ther. 24 (4), 583-594.
48. Morris, M.E., Levy, G., 1984. Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans. J. Pharm. Sci. 73, 1038-1041.
49. Nelson, E., Powell, J.R., Conrad, K., Likes, K., Byers, J., Baker, S., Perrier, D., 1982. Phenobarbital pharmacokinetics and bioavailability in adults. J. Clin. Pharmacol. 22 (2-3), 141-148.
50. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E., Zeldin, D.C., 2006. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34 (5), 880-886.
51. Pang, K.S., Durk, M.R., 2010. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J. Pharmacokinet. Pharmacodyn.
52. Pang, K.S., Terrell, J.A., 1981. Conjugation kinetics of acetaminophen by the perfused rat liver preparation. Biochem. Pharmacol. 30 (14), 1959-1965.
53. Perry, C.M., Markham, A., 1998. Sumatriptan. An updated review of its use in migraine. Drugs 55 (6), 889-922.
54. Perucca, E., Richens, A., 1979. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br. J. Clin. Pharmacol. 7 (2), 201-206.
55. Prescott, L.F., 1980. Kinetics and metabolism of paracetamol and phenacetin. Br. J. Clin. Pharmacol. 10 (Suppl 2), 291S-298S.
56. Rawlins, M.D., Henderson, D.B., Hijab, A.R., 1977. Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur. J. Clin. Pharmacol. 11 (4), 283-286.
57. Rowland, M., 2007. Commentary on ACCP position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 47(12), 1595-1596 (author reply 1597-1598).
58. 14C- nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J. Clin. Pharmacol. 45 (10), 1198-1205.
59. Scott, A.K., 1994. Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet. 27 (5), 337-344.
60. Siddoway, L.A., Roden, D.M., Woosley, R.L., 1984. Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am. J. Cardiol. 54 (9), 9D-12D.
61. 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects. Clin. Pharmacol. Ther. 88 (6), 824-830.
62. Varma, M.V., Panchagnula, R., 2005. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J. Pharm. Sci. 94 (8), 1694-1704.
63. Viswanathan, C.T., Booker, H.E., Welling, P.G., 1978. Bioavailability of oral and intramuscular phenobarbital. J. Clin. Pharmacol. 18 (2-3), 100-105.
64. Viswanathan, C.T., Booker, H.E., Welling, P.G., 1979. Pharmacokinetics of phenobarbital following single and repeated doses. J. Clin. Pharmacol. 19 (5-6), 282-289.
65. Vozeh, S., Haefeli, W., Ha, H.R., Vlcek, J., Follath, F., 1990. Nonlinear kinetics of propafenone metabolites in healthy man. Eur. J. Clin. Pharmacol. 38 (5), 509-513.
66. Warner, P.E., Brouwer, K.L., Hussey, E.K., Dukes, G.E., Heizer, W.D., Donn, K.H., Davis, I.M., Powell, J.R., 1995. Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm. Res. 12 (1), 138-143.
67. Wilensky, A.J., Friel, P.N., Levy, R.H., Comfort, C.P., Kaluzny, S.P., 1982. Kinetics of phenobarbital in normal subjects and epileptic patients. Eur. J. Clin. Pharmacol. 23 (1), 87-92.
68. Yamane, N., Tozuka, Z., Sugiyama, Y., Tanimoto, T., Yamazaki, A., Kumagai, Y., 2007. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 858 (1-2), 118-128.
69. Yska, J.P., Essink, G.W., Bosch, F.H., Lankhaar, G., van Sorge, A.A., 2000. Oral bioavailability of phenobarbital: a comparison of a solution in Myvacet 9-08, a suspension, and a tablet. Pharm. World Sci. 22 (2), 67-71.
70. Zhou, X.J., Garner, R.C., Nicholson, S., Kissling, C.J., Mayers, D., 2009. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J Clin Pharmacol.